|
Volume 271, Number 48,
Issue of November 29, 1996
pp. 30709-30716
©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
Protein Unfolding by Peptidylarginine Deiminase
SUBSTRATE SPECIFICITY AND STRUCTURAL RELATIONSHIPS OF THE
NATURAL SUBSTRATES TRICHOHYALIN AND FILAGGRIN*
(Received for publication, September 13, 1995, and in revised form, May 28, 1996)
Edit
Tarcsa
,
Lyuben N.
Marekov
,
Giampiero
Mei
,
Gerry
Melino
,
Seung-Chul
Lee
§ and
Peter M.
Steinert
¶
From the Laboratory of Skin Biology, NIAMS, National Institutes of
Health, Bethesda, Maryland 20892, Istituto Dermopatico
dell'Immacolata, Biochemistry Laboratories at Department of
Experimental Medicine and Biochemical Sciences, University Tor Vergata,
Rome 00133, and Department of Biology, University of L'Aquila,
L'Aquila 67100, Italy
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
FOOTNOTES
Acknowledgments
REFERENCES
ABSTRACT
Peptidylarginine deiminases, which are commonly
found in mammalian cells, catalyze the deimination of protein-bound
arginine residues to citrullines. However, very little is known about
their substrate requirements and the significance or consequences of this postsynthetic modification. We have explored this reaction in vitro with two known substrates filaggrin and
trichohyalin. First, the degree and rate of modification of arginines
to citrullines directly correlates with the structural order of the
substrate. In filaggrin, which has little structural order, the
reaction proceeded rapidly to >95% completion. However, in the highly
-helical protein trichohyalin, the reaction proceeded slowly to
about 25% and could be forced to a maximum of about 65%. Second, the
rate and degree of modification depends on the sequence location of the
target arginines. Third, we show by gel electrophoresis, circular dichroism, and fluorescence spectroscopy that the reaction interferes with organized protein structure: the net formation of 10%
citrulline results in protein denaturation. Cyanate modification of the
lysines in model -helix-rich proteins to homocitrullines also
results in loss of organized structure. These data suggest that the
ureido group on the citrulline formed by the peptidylarginine deiminase enzyme modification functions to unfold proteins due to decrease in net
charge, loss of potential ionic bonds, and interference with H
bonds.
INTRODUCTION
Peptidylarginine deiminases (PAD)1
(protein-arginine deiminase, protein-L-arginine
iminohydrolase, EC 3.5.3.15) are a family of
Ca2+-dependent enzymes that catalyze the
post-translational deimination of protein-bound arginine residues to
citrullines (1, 2, 3, 4, 5, 6, 7). Biochemical studies have revealed that there are
two or possibly three different types of PAD enzymes (8, 9, 10). The type
1 enzyme is found in the epidermis and to a lesser extent in the
uterus. Type 2 enzyme is expressed in muscle, brain, uterus, spinal
cord, pancreas, spleen, salivary gland, stomach, thymus, pituitary,
submaxillary gland, etc. Type 3 enzyme is present in hair follicle
tissue and in the epidermis. The rat and mouse type 2 (11, 12) and part
of the mouse uterus type 1 (13) enzymes have been cloned and sequenced.
A recent report indicated that the sequence of the type 3 enzyme is
highly homologous to the type 2 enzyme (14).
Little is known about the precise function(s) or target substrates of
the PAD enzyme in most tissues. PAD deimination was suggested to modify
the action of trypsin-like enzymes (4) and trypsin inhibitors (15, 16),
interfere with intermediate filament (IF) assembly (17, 18, 19) and play a
role in rapid cellular turnover in tissues of secretory activity (9).
However, the physiological significance of each of these has not been
established.
On the other hand, there are two well documented protein substrates of
PAD. One is the filaggrin, which is present only in orthokeratinizing
epidermis. Filaggrin can bundle keratin IF into tight arrays in
vitro and in vivo (20) due to ionic interactions of its
basic charges with the negatively charged keratin IF (21). Filaggrin is
largely (22) or partly (19) deiminated in differentiated human stratum
corneum cells, rendering it neutral in charge. The second known
substrate protein is trichohyalin (THH), which is a major
differentiation product of the inner root sheath cells of the hair
follicle, and of the medulla in the hair fiber and related structures
such as porcupine quills (23, 24, 25, 26). THH is also expressed to a lesser
extent in interfollicular normal human epidermis, and foreskin
epidermis (27, 28). Isolated sheep (25, 29), human, and pig (27, 30)
THH are highly insoluble proteins. Secondary structure predictions
showed that they are likely to adopt a single-stranded -helical
structure (31). A variety of studies have now established that THH is a
target substrate protein for deimination by PAD in hair follicle cells
(3, 19, 32, 33, 34, 35, 36).
However, the details of the reaction of PAD with filaggrin and THH or
other substrates remain unclear. Moreover, the function of the PAD
modification events in these tissues remains unknown. In this study, we
have explored the substrate specificity of the type 2 PAD using as
substrates mouse filaggrin, human THH, and other model peptides of
related structures. Our data reveal certain sequence and substrate
structural requirements for the enzyme and, for the first time, the
consequences of its action, which provide insights into its function in
the skin.
EXPERIMENTAL PROCEDURES
Materials
The following were purchased: type 2 rabbit
skeletal muscle PAD (PanVera Corp., Madison WI); sequencing grade Asp-N
protease (Boehringer Mannheim); precast Tris-glycine, Tricine, and
isoelectric focusing (pH 3-7 and 3-10) gels (Novex, San Diego, CA);
horse heart myoglobin, protamine sulfate, and a synthetic copolymer polypeptide of average composition
alanine6-lysine5-glutamate2-tyrosine1 (20,000-50,000 molecular weight; Sigma). Mouse
filaggrin was isolated and purified as described (20, 21). Several
synthetic peptides (Table I) were purified by HPLC and quantitated by
amino acid analysis.
Analytical Methods
Samples were subjected to acid
hydrolysis (5.7 M HCl, 110 °C, 22 h, in
vacuo), and their amino acid compositions were determined on a
Beckman 6300 amino acid analyzer. The amount of citrulline was
corrected for hydrolytic losses to ornithine. Citrulline and ornithine
eluted at 15.7 and 50.1 min, near glutamic acid and lysine,
respectively. Protein concentrations of samples were determined according to Bradford (37), and by amino acid analysis.
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was done according to
Laemmli (38).
Expression and Purification of Human Trichohyalin Domain
8
The construct of THH-8 (residues 1250-1849 predicted by
secondary structure analysis) for expression was made by polymerase chain reaction with primers from the sequences of domain 8 (31), and
confirmed by sequencing. The ATG start and TGA stop codons were
inserted at the positive and negative polymerase chain reaction primers, respectively. This construct was cloned into the pET-11a vector (Novagen, Madison, WI) (39). The vector was transformed into the
BL 21 E. coli strain, and bacteria (1-5-liter cultures) were grown in Terrific Broth (Sigma; modified,
supplemented with 10 g/liter glucose and 50 µg/ml carbenicillin)
until A600 nm = 1.2. Protein expression was
induced with 1 mM
isopropyl-2-thio- -D-galactopyranoside for 3 h
(final A600 nm = 2.5). Bacterial pellets
(10,000 × g, 30 min) were lysed and DNase-digested as
described (40). The inclusion bodies were isolated by centrifugation
(27,000 × g, 5 min) and washed in 50 mM
Tris-HCl (pH 8.0) 1 mM EDTA, 1% Triton X-100 several
times. The pellet was solubilized in 8 M urea, 20 mM Tris-HCl (pH 8.8), loaded, and chromatographed at a flow
rate of 15 ml/h on a Sepharose Q Fast Flow column equilibrated in this
buffer. The column was then washed in the same buffer without urea, and
the THH-8 was eluted with a linear gradient of 0-1.0 M
NaCl. THH-8 was identified by Western blotting with poly- and
monoclonal anti-pig THH antibodies (27). The purity and concentrations
of the combined fractions was determined by amino acid analysis.
Modifications of Proteins and Peptides with PAD
THH-8 (50 µg/ml) was incubated with PAD at 37 °C at different
enzyme:substrate molar ratios (between 1:1000 and 10:1) in a buffer of
20 mM Tris-HCl (pH 8.8), 0.3 M NaCl, 1 mM EDTA, 10 mM dithiothreitol, 5 mM
CaCl2, and the reaction was terminated as required by the
addition of EDTA (10 mM final concentration). To determine
the extent of reaction (i.e. appearance of citrulline), samples obtained at low enzyme:substrate ratios were acid-hydrolyzed directly for amino acid analysis. Control experiments showed that the
PAD enzyme alone does not generate citrulline during reaction. When
high enzyme:substrate ratios were used, the reaction products were
first resolved on 10% Tricine gels (Novex), transferred onto polyvinylidene difluoride membranes, and after a brief staining with
Coomassie Brilliant Blue, the appropriate THH bands were cut out and
hydrolyzed. Aliquots of the samples were resolved on 8% SDS-PAGE, and
either pH 3-7 or 3-10 isoelectric focusing gels. Mouse filaggrin (10 µM) was incubated as described for THH-8 at an
enzyme:substrate molar ratio of 1:1000 in the Tris buffer at pH 8.0. The degree of modification was likewise determined by amino acid
analysis. Synthetic peptides were deiminated at an enzyme:arginine
molar ratio of 1: 40,000 at pH 8.0 at 37 °C for 3 h. The
products were separated by HPLC on a reverse phase column prior to
amino acid analysis.
Separation of Peptides From THH-8 and Filaggrin
Unmodified
and modified THH-8 and filaggrin samples in 0.1 M
NH4HCO3 were digested with Asp-N protease at a
ratio of 1:2,000 (by weight) at 23 °C for up to 18 h. The
fragments were separated by HPLC on a narrow bore reverse phase column
(218TP52) (Vydac, Hesperia, CA) using a 10-60% acetonitrile gradient
containing 0.08% trifluoracetic acid in 50 min at 0.23 ml/min flow
rate. The eluted peaks were dried, and their amino acid compositions were determined and sequenced.
Peptide Microsequencing
Peptides were covalently attached
to a Sequelon-AA polyvinylidene difluoride solid support (Millipore,
Bedford, MA) and sequenced by Edman degradation in a LF3000 gas phase
sequencer (Porton) using the manufacturer's recommended procedure
number 39. PTH-derivatives were separated by on-line reverse-phase HPLC
(using 3.5% tetrahydrofuran in buffer A; Ref. 41) with System Gold
software. PTH-citrulline eluted at 6.1 min, immediately after
PTH-threonine.
Chemical Modification of Proteins with Cyanate
Samples of
THH-8 (0.14 mg/ml), horse heart myoglobin (0.7 mg/ml), and a commercial
random synthetic polypeptide (molecular weight 20,000-50,000) of
average composition
alanine6-lysine5-glutamate2-tyrosine1 (0.5 mg/ml) were reacted with potassium cyanate for up to 24 h to
convert lysine residues to homocitrullines (42). After reaction, the
protein samples were equilibrated by dialysis into 10 mM
Tris-HCl (pH 7.5). The extent of reaction was followed by acid
hydrolysis, although 35% of the homocitrulline was converted back to
lysine under the conditions used (42). Homocitrulline eluted from the Analyser column at 26.0 min.
Physicochemical Measurements
THH-8 (0.05-0.1 mg/ml), mouse
filaggrin (0.2 mg/ml), myoglobin (0.5 mg/ml), or copolymer polypeptide
(0.35 mg/ml) solutions were equilibrated into the same buffer as used
for the PAD reaction. Steady state fluorescence excitation and emission
spectra were recorded on a photon-counting spectrofluorometer
(Fluoromax Instruments, Paris, France). The bandwidths of excitation
and emission monochromators were in the range of 2-4 nm. In all
fluorescence experiments, spectra were corrected for Raman
contributions by buffer base-line subtraction. Absorption and circular
dichroism (CD) measurements were carried out using a Jasco Uvidec 650 spectrophotomer and Jasco 600 and 700 spectropolarimeters,
respectively. In both cases, 0.1-cm quartz cuvettes were used. The
sample holders were thermostated before and during measurements, using
external circulation. Protein concentrations were measured by amino
acid analyses to calculate molar ellipticity values for estimation of
helix contents. In addition, -helical contents were routinely
estimated by use of curve-fitting algorithms from the shape of the
spectra, especially in the case of the copolymer polypeptide of
heterogeneous molecular weight. The two methods yielded identical
estimates.
RESULTS AND DISCUSSION
To date, studies with the PAD enzyme have utilized mostly model
peptide substrates. The purpose of the present study was to explore the
specificity and structural requirements of the PAD enzyme using the
known in vivo substrate proteins mouse filaggrin and a more
soluble cloned portion of human THH (THH-8). For the enzyme, we have
used the commercially available type 2 enzyme from rabbit skeletal
muscle. While there are minor differences in the antigenicity and
apparent molecular weights of the type 2 ("ubiquitous") and 3 ("hair follicle") enzymes, they have been reported to have
essentially identical substrate specificities (8, 9, 14).
PAD Modification of Mouse Filaggrin
Mouse filaggrin (30 kDa)
contains 16% arginine (40 residues/mol) (43). By amino acid analysis,
an average of 95% were deiminated to citrullines within 3 h using
an enzyme:substrate ratio of 1:1000 (Fig.
1A), so that the total citrulline content was
>15%. To determine whether the 95% conversion meant that all
arginines were equally modified or whether ~2 were not modified at
all, the filaggrin sample was digested with Asp-N protease, and the 15 fragments encompassing the entire sequence were separated by
reverse-phase HPLC. The peptides were subjected to acid hydrolysis, and
their amino acid compositions were determined. In all fragments ~95% of the arginine was modified. In confirmation, one fragment containing 4 arginines (Table I) was directly sequenced by Edman
degradation. At each expected arginine residue position, >95%
citrulline was recovered. The partially and fully modified filaggrin
migrated considerably more slowly by SDS-gel electrophoresis (Fig.
1B). While this phenomenon has not been described previously
with model protein substrates, two studies have reported progressive
decreases in the mobility of human (19) and rat (22) filaggrins
partially deiminated in vivo.
Fig. 1.
PAD deimination of mouse filaggrin.
A, conversion rate of arginines to citrullines using a
PAD:filaggrin ratio of 1:1000. The data are the averages of three
experiments. B, SDS-PAGE for 0, 10, 20, 40, 60, 120, 180, and 1080 min, respectively.
[View Larger Version of this Image (33K GIF file)]
Expression and Purification of Human THH-8
Although THH can
be easily purified from hair follicle tissue (25) or pig tongue
epithelium (30) because of its extraordinary insolubility, this
precludes its use in in vitro enzymatic reactions. Instead,
we have expressed in bacteria domain 8, the largest domain representing
about 30% of human THH. This domain consists of numerous irregular
peptide repeats of about 26 residues that are typical of the entire
human THH sequence (31). The 80-kDa protein was expressed in E. coli and purified to homogeneity (Fig. 2,
inset, lane 1). Its amino acid composition is as
expected from its known sequence (including 137 arginines, 22.8%), and
is ~86% -helical as determined by CD (see Fig. 5B,
line 1). Since this result is exactly as predicted for this
THH sequence and is consistent with the available data for native pig
tongue THH (31), the data indicate that the bacterially expressed
protein had properly adopted the native structural configuration. The
THH-8 cross-reacts with existing monoclonal (Fig. 2, inset,
lane 2) and polyclonal (data not shown) antibodies (27). In
the pH 8.8 buffer, its solubility was limited to ~100 µg/ml.
Fig. 2.
Purification of human THH-8. Human
recombinant THH-8 was obtained as an enriched fraction from urea
dissolution of the bacterial inclusion bodies, and then recovered in
pure form by chromatography on a Sepharose Q Fast Flow column
(arrow). Inset, SDS-PAGE of samples: lane
1, Coommassie Brilliant Blue staining; lane 2, Western
blot using a monoclonal anti-pig THH antibody.
[View Larger Version of this Image (16K GIF file)]
Fig. 5.
Circular dichroism shows that PAD promotes
loss of secondary structure in filaggrin and THH-8. A, CD
spectra of mouse filaggrin (line 1) and of filaggrin in
which >95% of the arginines had been modified to citrullines by PAD
(line 2). B, CD spectra of THH-8 (line
1) or of THH-8 after ~25% (line 2), ~40%
(line 3), and ~65% (line 4) conversion of
arginines to citrullines by PAD. C, urea unfolding titration
curves of THH-8 by urea calculated on the basis of the CD signal
obtained at 222 nm. The arrows on the left
indicate the corresponding values obtained with PAD from line
3 (PAD 1) and line 4 (PAD 2) of
panel B.
[View Larger Version of this Image (20K GIF file)]
PAD Modification of Human THH-8
The conversion of arginines
to citrullines with time as a function of enzyme concentration was
assayed by amino acid analysis and was markedly slower in THH-8 than
for filaggrin. Using the low enzyme:substrate ratios used with
filaggrin (1:1000), very little modification occurred (Fig.
3A, line 1). At ratios of
1:100-1:50, about 20-25% of the arginine content was modified
(line 2), but a maximum of up to about 65% could be
achieved at higher ratios (up to 10:1) (line 3). As was
found for filaggrin, the migration of the modified THH-8 on SDS gels
was reduced in a gradual fashion so that its
Mapp was about 160 kDa (Fig. 3B). By
isoelectric focusing, bands of progressively more acidic charge were
seen (Fig. 3C), from pI ~6.5 for unmodified THH-8, which
only enters the gel poorly, to pI 4.8, commensurate with the expected
loss of arginine. We also noted that partially to maximally modified
THH-8 samples became more soluble (>0.5 mg/ml).
Fig. 3.
PAD deimination of human THH-8. A,
conversion rate of arginines to citrullines with PAD:THH-8 molar ratios
of 1:1000 (line 1), 1:100-1:50 (line 2), or
1:30-10:1 (line 3). The data are the averages of three to
five experiments. B, SDS-PAGE of a 1:30 reaction for 0, 5, 10, 20, 40, 60, 120, 300, and 1080 min, respectively, and stained with
Coomassie Brilliant Blue. M, molecular weight markers of
indicated sizes. C, as in B, except same samples were resolved by isoelectric focusing on a pH 3-7 gel. S,
standard markers (Bio-Rad) of indicated pI values.
[View Larger Version of this Image (38K GIF file)]
We next wanted to determine why the modification of THH-8 proceeded to
only about 65%. Aliquots of unmodified and maximally modified THH-8
were digested with Asp-N, and the fragments were separated on reverse
phase HPLC. In the latter, the elution times of the peaks were largely
unchanged, probably because most peptides were relatively long (>20
residues), but the peaks became more broad (data not shown). This may
be because each peak constituted a mixture of forms of a single peptide
whose several arginines were modified to varying extents. By amino acid
analyses, most peptides showed 30-70% modification. Many peptides
were then partially or completely sequenced, encompassing about 40% of
the THH-8 protein (see Table I for partial list). Due to the highly
repetitive nature of THH-8, these are representative of >80% the
protein. Indeed, we found that the citrulline contents varied across
the broad peptide peaks. However, in general, most of the arginines were converted to citrulline by >75%, except those arginines followed by a glutamic acid residue, which were only slightly modified at 5%.
Since about one-third of the arginines are followed by glutamic acid
residues, this provides a simple explanation for the observed maximal
extent of modification. In the special cases of two (Table I, peptides
2, 5, and 7) or three (peptide 1) consecutive arginines in THH-8, the
first was completely but the second and/or third were modified less
efficiently. In addition, intact modified THH-8 was sequenced from its
amino terminus (Table I, peptide 1) to show that arginines followed by
aspartic acid residues were modified to near completion.
Progressive Decreases in The Mobilities of Filaggrin and THH-8
after PAD Modification May Be Due to Alterations of Their Conformation
and Charge
Changes in mobilities of proteins in SDS fields are
often due to changes in conformation and/or charge (44). To further explore this issue, we included 8 M urea in the SDS gel and
the sample buffer prior to boiling. In both cases, the unmodified as
well as partially modified filaggrin (Fig.
4A) and THH-8 (Fig. 4B) samples
all migrated at the decreased rates of ~60 or ~160 kDa,
respectively, close to the modified forms. Both of these proteins have
unusual structures. Filaggrin is thought to possess a -turn
secondary structure (21) so that the molecule adopts a compact form,
which would be expected to be unfolded by urea into a larger molecular
volume. THH-8, like intact THH itself, is thought to form a
single-stranded -helix in which successive turns of the helix are
stabilized by intrachain ionic bonds (31, 45) to form an elongated
rodlike shape, which might not be completely unfolded by SDS. In these
cases, urea may be a more efficient protein denaturant than SDS.
Indeed, numerous other reports have documented that SDS denaturates
some proteins incompletely (44, 46, 47). When arginine is converted to
citrulline, the guanidino group is replaced by a ureido group. This
modification would be expected to destroy many potential salt bonds and
interfere with H bonds, which could thus destabilize the protein
structures, resulting in unfolding. Thus we speculate that the
progressive mobility decreases caused by partial PAD modification may
be related to progressive unfolding, i.e. maximal
modification of filaggrin and THH-8 by PAD may result in changes in
structure that are comparable with denaturation by urea.
Fig. 4.
SDS-PAGE of unmodified or partially modified
filaggrin and THH-8 in the presence of 8 M urea causes
anomalous migration. Samples from Fig. 1B
(A) and Fig. 3C (B) (except the
samples taken at 1080 min) were made to 8 M urea before
boiling in SDS sample buffer, and run on standard Laemmli gels (8%
gel) except that the gel also contained ~8 M urea.
[View Larger Version of this Image (72K GIF file)]
In addition, the mobility changes may be due to changes in charge of
the target protein. This is especially true of arginine-rich basic
proteins, and proteins rendered neutral or acidic in charge following
chemical modification (48, 49, 50). For example, the mutation of a single
arginine residue resulted in significantly decreased mobility of a
protein (51). It is possible that the net gain of many more acidic
charges on the proteins arising from loss of arginines may in effect
explode the proteins due to adverse charge interactions. Consistent
with this, we could modify 75% of the arginines of protamine sulfate
to generate a citrulline content of ~50%. In this case, the protein
became neutral in charge, soluble in SDS, and migrated with an apparent
molecular weight twice its expected size (data not shown). Mobility
changes were also seen with histones (final citrulline contents of up
to ~10%).
Thus in the cases of the arginine-rich proteins THH-8 and filaggrin,
the unusual mobility changes induced by PAD modification may be due to
a combination of structure and charge changes (44, 51). Further studies
on other model proteins containing high contents of arginine, lysine,
and acidic residues seem desirable to resolve these issues.
Biophysical Measurements Confirm That PAD Modification Reduces the
Degree of Structural Order of Proteins
The postulated structural
consequences of the PAD reaction were examined directly using
biophysical analyses. As expected (21), by CD, filaggrin is mostly
-turn in structure (Fig. 5A, line
1), but after complete modification, the spectrum becomes flat
(line 2), indicative of a loss of organized structure
(52, 53, 54). On the other hand, THH-8 is ~86% -helical (Fig. 5B, line 1), as predicted from its sequence, and
it is slightly more ordered than observed for intact native pig tongue
THH (31). Conversion of 25% (line 2), 40% (line
3), or 65% (line 4) of its arginines, generating
citrulline contents of ~5.5%, 9%, and 15%, reduced its -helical
contents to ~60%, 35%, and to no organized structure, respectively.
This loss of -helicity observed in lines 3 and
4 is comparable with denaturation of the THH-8 by 2.5 M or 4.5 M urea, respectively (Fig.
5C).
We also used fluorescence spectroscopy. The spectrum of THH-8 upon
excitation at 280 nm (to visualize both tyrosines and tryptophans) is
blue-shifted, and the peak at 312 nm suggests that the two tryptophan
residues are buried within the protein structure (Fig. 6A, solid line). However,
following maximal modification by PAD, the red shift in the
fluorescence spectrum toward longer wavelengths (dotted
line) is similar to that of THH-8 fully denatured in 6 M urea (dashed line). These data indicate that
upon maximal modification by PAD, the two tryptophans have become
exposed and thus freely mobile, which is consistent with the concept of
loss of organized structure.
Fig. 6.
Fluorescence spectroscopy shows that PAD
promotes unraveling of THH-8 structure. A, steady state
fluorescence spectra of THH-8 (solid line), THH-8 maximally
modified by PAD (dotted line), and THH-8 denatured by 6 M urea (dashed line). Excitation was at 280 nm.
B, anisotropy measurements were made in the cuvette after
the addition of increasing aliquots of PAD enzyme, followed by 60-min
reaction intervals (arrows). Based on amino acid analyses, all protein remained in solution. The three additions caused ~15%, 30%, and 45% modification, respectively.
[View Larger Version of this Image (19K GIF file)]
Furthermore, steady state fluorescence anisotropy measurements were
made (Fig. 6B). On addition of increasing amounts of PAD enzyme to the cuvette containing the THH-8 solution, the anisotropy decreased from 0.21 (unmodified THH-8) to less than 0.15 in protein in
which ~40% of the arginines had been modified (~11% citrulline content). This decrease clearly indicates the absence of protein dimerization, as also suggested by the SDS-PAGE data (Figs. 1 and 3),
and confirms that the protein had become unfolded by the PAD
modification reaction.
Introduction of Homocitrullines Also Interferes with Protein
Structures
The foregoing data suggest that the modification of
arginines to citrullines results in a progressive unfolding of the
proteins equivalent to that obtained with 4.5 M urea. One
possible explanation for this phenomenon is that the substituted urea
side chain of citrulline interferes with ionic and H-bonding
interactions. To test this hypothesis, we inserted homocitrulline into
proteins by chemical conversion of the -NH2 groups of
their lysine side chains with cyanate. We used three proteins of widely
differing lysine contents but which have highly ordered structures:
THH-8 (5.5% lysine, 86% -helix), intact myoglobin (12.7% lysine,
70% -helix), and a commercially available random copolymer
polypeptide (35.7% lysine, 90% -helix). Reaction with cyanate for
up to 24 h resulted in high degrees of conversion of lysines to
homocitrullines and retention of their high solubilities, based on
amino acid analyses (data not shown). By CD, the -helical content of
THH-8 was estimated to have been reduced from 86% to ~60% (1.6%
homocitrulline), ~20% (3% homocitrulline), and to ~10% (4%
homocitrulline) (Fig. 7A, lines
1-4, respectively). In the case of the lysine-rich synthetic copolymer peptide, the -helical content was reduced from 90% to
~40% (5% homocitrulline), ~10% (17% homocitrulline), and to no
structure (21% homocitrulline) (Fig. 7B). Likewise, with
myoglobin, the -helical content was reduced from ~70% to 60%
(2% homocitrulline), ~15% (7% homocitrulline), and to <10% (10%
homocitrulline) (Fig. 7C). In this case, the loss of
structure with retained heme group and disulfide bonds was similar to
that seen upon denaturation in acid solutions (53, 55, 56).
Fig. 7.
Insertion of homocitrullines also denatures
proteins. CD spectra were taken of THH-8 (A), a
synthetic copolymer polypeptide (B), and myoglobin
(C) after reaction with cyanate to convert up to 90% of
lysines to homocitrullines. The numbers refer to the degrees
of cyanate modification, as indicated under "Results and
Discussion." In B the -helical contents were estimated
by computer analyses of the line shapes since the polypeptide is heterogeneous in molecular weight. In D, the estimated
-helical contents of the three proteins were plotted
versus homocitrulline content (closed symbols).
The data for THH-8 and citrulline (from Fig. 5B) are shown
for comparison (open symbols).
[View Larger Version of this Image (20K GIF file)]
These data show that the insertion of homocitrulline even in low
amounts begins to reduce the high -helical contents of these proteins. Taken together, the degree of loss of structure correlates with the degree of modification (Fig. 7D). Indeed,
comparison of the THH-8 data suggests that homocitrulline seems to be
even more effective in unfolding of protein structure than citrulline. Therefore, these data support the concept that the ureido group of the
citrulline or homocitrulline side chains promotes the observed interference in organized protein structure.
Substrate Structural Requirements for PAD Modification
While
some information on the specificity of the PAD enzyme reaction has
become available using arginine derivatives or short peptides (57),
other data have been generated using model protein substrates, probably
unrelated to in vivo substrates. For example, in soybean
trypsin inhibitor, one arginine in its active site, located on an
external loop, could be modified very rapidly (enzyme:substrate ratio
of 1:50 in 10 min) (15), while nine others could be converted more
slowly within 5 h (57). However, in mouse plasma trypsin inhibitor, which is largely -helical in structure, the reaction proceeds at a rate one-tenth that for soybean trypsin inhibitor (15,
16). On the other hand deimination of IF protein chains occurs only in
the non- -helical head and tail domains (18). Together with the
present data on the natural substrates filaggrin and THH-8 (Figs. 1 and
3; Table I), these observations suggested that the PAD reaction may be
dependent on substrate structure.
To explore this issue further, we examined the structural requirements
of the PAD enzyme reaction with synthetic peptides of filaggrin, THH,
and keratins 1 and 10 (Table I). Following deimination at an
enzyme:arginine ratio of 1:40,000, the peptides were purified by HPLC,
analyzed to determine their citrulline contents, and sequenced (Table
I). In most cases the peptide peaks from the HPLC column became
broader, suggesting a heterogeneous population of molecules with
varying degrees of arginine modification. The mimetic filaggrin peptide
of -turn structure was 95% deiminated, as for the same sequence in
intact mouse filaggrin. In the keratin 10 1A peptide of -helical
structure, an average of 70% of the arginines were modified, of which
the second arginine from the amino terminus and the arginine third from
the carboxyl terminus were converted ~50%, while the two internal
arginines were modified 85%, and the -helical structure of the
peptide was lost. Similarly, in the shorter -helical keratin 1 1A
peptide, the amino-terminal arginine was only slightly modified. By CD
the longer natural and mimetic THH peptides were >90% -helical,
and thus are more closely related to the structure of THH-8. While
their -helical structures were lost, the degrees of modification of
the arginines varied widely. The amino-terminal arginine was not
modified at all; most single arginines were completely modified; a
single arginine followed by glutamic acid was modified only <10%; a
single arginine followed by an aspartic acid residue was completely
modified; and in the cases of two consecutive arginines, the second was less modified. To address what happens when two consecutive arginines preceded a glutamic acid, a mimetic THH peptide showed that the first
was modified 70% and the second 50% (Table I). In general these data
are highly comparable with those obtained for the same sequences in
THH-8. By CD, the short THH peptide 5 had no organized structure in
solution. The first arginine was partly modified; the second and third
arginines were >90% modified; but the fourth arginine, followed by a
glutamic acid residue, was significantly modified to 60-80%, to a
much higher degree than in THH-8 or the two longer synthetic
peptides.
Altogether, the present data accumulated from mouse filaggrin, human
THH-8, and synthetic mimetic peptides show that arginines located near
the amino terminus are poorly modified, arginines in highly -helical
protein structures are only slowly modified to near completion, and
arginines in proteins of little structural order are rapidly modified
to near completion. However, a single arginine followed by a glutamic
acid residue is only poorly modified in an -helical protein, but
significantly modified in proteins of low structural order; in the rare
cases of two consecutive arginines, the first was always modified to a
greater extent than the second arginine. Thus the PAD reaction is
dependent on both substrate structure and precise sequence
around the arginine residues.
Concluding Remarks
The present studies have identified
several important properties of the PAD enzyme. First, in general,
proteins such as filaggrin having only a simple -turn secondary
structure were quickly and quantitatively modified, while those with
high -helical contents were modified more slowly. Second, certain
sequence preferences were identified. Thus the activity of the PAD
enzyme is markedly affected by both substrate structure and substrate
sequence in the vicinity of the arginines. Third, of likely significant
biological importance, the present data show that the structural
properties of the natural substrates THH and filaggrin are changed on
extensive PAD modification. Modification of sufficient arginines to
introduce a net citrulline content of 5% begins to disorder
organized protein structures, and a net content of 10% causes loss
of structure (Figs. 5 and 6). This may be attributable to the ureido
group of the citrulline, since a charged electron donor group is
modified to an electron acceptor group. This would be expected to
interfere with the stabilization of H bonds and is no longer able to
form ionic bonds. Chemical modification of lysines to homocitrullines may disorder organized protein structures in the same way (Fig. 7). The
unfolding of filaggrin and THH by PAD in the skin would be expected to
significantly alter their interactions with IF and transglutaminases
(22, 26, 36, 58, 59), questions for which additional experiments will
now be required.
FOOTNOTES
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Present address: Dept. of Dermatology, Chonnam University Hospital,
Kwangju City 50-190, Republic of Korea.
¶
To whom all correspondence should be addressed: National
Institutes of Health, Bldg. 6, Rm. 425, 9000 Rockville Pike, Bethesda, MD 20892-2755. Tel.: 301-496-1578; Fax: 301-402-2886; E-mail: pemast{at}helix.nih.gov.
1
The abbreviations used are: PAD,
peptidylarginine deiminase; IF, intermediate filament(s); PAGE,
polyacrylamide gel electrophoresis; THH, trichohyalin; THH-8, domain 8 of human trichohyalin; HPLC, high performance liquid chromatography;
PTH, phenylthiohydantoin; Tricine,
N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine.
Acknowledgments
We are indebted to Drs. A. Chrambach, A. Finazzi-Agrò, P. McPhie, M. Paci, and D. Parry for advice
concerning the anomalous gel migration and structural properties of
PAD-modified proteins. We thank Drs. E. Candi and B. Ciani for numerous
helpful suggestions and encouragement, G. Poy for the synthesis of the
oligonucleotides and most of the peptides used in this work, and W. Idler for technical assistance.
REFERENCES
-
Rogers, G. E.
(1964)
in
The Epidermis (Montagna, W., and Lobitz, W., eds), pp. 179-203, Academic Press, New York
-
Rogers, G. E., Harding, H. W. J., and Llewellyn-Smith, I. J.
(1977)
Biochim. Biophys. Acta
495,
159-175
[Medline]
[Medline]
[Order article via Infotrieve]
-
Rogers, G. E., and Taylor, L. D.
(1977)
in
Advances in Experimental Medicine and Biology (Friedman, M., ed), Vol. 86A, pp. 283-294, Plenum Publishing Corp., New York
-
Kubilus, J., Waitkus, R. W., and Baden, H. P.
(1980)
Biochim. Biophys. Acta
615,
246-251
[Medline]
[Medline]
[Order article via Infotrieve]
-
Fujisaki, M., and Sugawara, K.
(1981)
J. Biochem. (Tokyo)
89,
257-263
[Medline]
[Abstract/Free Full Text]
-
Takahara, H., Oikawa, Y., and Sugawara, K.
(1983)
J. Biochem. (Tokyo)
94,
1945-1953
[Medline]
[Abstract/Free Full Text]
-
Kubilus, J., and Baden, H.
(1983)
Biochim. Biophys. Acta
745,
285-291
[Medline]
[CrossRef][Medline]
[Order article via Infotrieve]
-
Watanabe, K., Akiyama, K., Hikichi, K., Ohtsuka, R., Okuyama, A., and Senshu, T.
(1988)
Biochim. Biophys. Acta
966,
375-383
[Medline]
[Medline]
[Order article via Infotrieve]
-
Takahara, H., Tsuchida, M., Kusubata, M., Akutsu, K., Tagami, S., and Sugawara, K.
(1989)
J. Biol. Chem.
264,
13361-13368
[Medline]
[Abstract/Free Full Text]
-
Terakawa, H., Takahara, H., and Sugawara, K.
(1991)
J. Biochem. (Tokyo)
110,
661-666
[Medline]
[Abstract/Free Full Text]
-
Watanabe, K., and Senshu, T.
(1989)
J. Biol. Chem.
264,
15255-15260
[Medline]
[Abstract/Free Full Text]
-
Tsuchida, M., Takahara, H., Minami, N., Arai, T., Kobayashi, Y., Tsujimoto, H., Fukazawa, C., and Sugawara, K.
(1993)
Eur. J. Biochem.
215,
677-685
[Medline]
[Medline]
[Order article via Infotrieve]
-
Tsuchida, M., Minami, N., Tsujimoto, H., Fukazawa, C., Takahara, H., and Sugawara, K.
(1991)
Agric. Biol. Chem.
55,
295-297
[Medline]
[Medline]
[Order article via Infotrieve]
-
Nishijyo, T., Kawada, A., Shiraiwa, M., and Takahara, H.
(1995)
J. Invest. Dermatol.
104,
577
-
Takahara, H., Okamoto, H., and Sugawara, K.
(1985)
J. Biol. Chem.
260,
8378-8383
[Medline]
[Abstract/Free Full Text]
-
Takahara, H., and Sugawara, K.
(1987)
Agric. Biol. Chem.
51,
1657-1664
-
Steinert, P. M., and Idler, W. W.
(1979)
Biochemistry
18,
5664-5669
[Medline]
[CrossRef][Medline]
[Order article via Infotrieve]
-
Inagaki, M., Takahara, H., Nishi, Y., Sugawara, K., and Sato, C.
(1989)
J. Biol. Chem.
264,
18119-18127
[Medline]
[Abstract/Free Full Text]
-
Senshu, T., Akiyama, K., Kanm, S., Asaga, H., Ishigami, A., and Manabe, M.
(1995)
J. Invest. Dermatol.
105,
163-169
[Medline]
[CrossRef][Medline]
[Order article via Infotrieve]
-
Steinert, P. M., Cantieri, J. S., Teller, D. C., Lonsdale-Eccles, J. D., and Dale, B. A.
(1981)
Proc. Natl. Acad. Sci. U. S. A.
78,
4097-4101
[Medline]
[Abstract/Free Full Text]
-
Mack, J. W., Steven, A. C., and Steinert, P. M.
(1993)
J. Mol. Biol.
232,
50-66
[Medline]
[CrossRef][Medline]
[Order article via Infotrieve]
-
Harding, C. R., and Scott, I. R.
(1983)
J. Mol. Biol.
170,
651-673
[Medline]
[CrossRef][Medline]
[Order article via Infotrieve]
-
Auber, L.
(1952)
Trans. R. Soc. Edinb.
62,
191-201
-
Birbeck, M. S. C., and Mercer, E. H.
(1957)
J. Biophys. Biochem. Cytol.
3,
223-230
[Abstract/Free Full Text]
-
Rothnagel, J. A., and Rogers, G. E.
(1986)
J. Cell Biol.
102,
1419-1429
[Medline]
[Abstract/Free Full Text]
-
O'Guin, W. M., Sun, T.-T., and Manabe, M.
(1992)
J. Invest. Dermatol.
98,
24-32
[CrossRef][Medline]
[Order article via Infotrieve]
-
O'Keefe, E. J., Hamilton, E. H., Lee, S.-C., and Steinert, P. M.
(1993)
J. Invest. Dermatol.
101,
65S-71S
[CrossRef]
-
Manabe, M., and O'Guin, W. M.
(1994)
Differentiation
58,
65-75
[Medline]
[CrossRef][Medline]
[Order article via Infotrieve]
-
Fietz, M. J., McLaughlan, C. J., Campbell, M. T., and Rogers, G. E.
(1993)
J. Cell Biol.
21,
855-865
-
Hamilton, E. H., Sealock, R., Wallace, N. R., and O'Keefe, E. J.
(1992)
J. Invest. Dermatol.
98,
881-889
[Medline]
[CrossRef][Medline]
[Order article via Infotrieve]
-
Lee, S.-C., Kim, I.-G., Marekov, L. N., O'Keefe, E. J., Parry, D. A. D., and Steinert, P. M.
(1993)
J. Biol. Chem.
268,
12164-12176
[Medline]
[Abstract/Free Full Text]
-
Rogers, G. E.
(1963)
J. Histochem. Cytochem.
11,
700-706
[Abstract]
-
Steinert, P. M., Harding, H. W. J., and Rogers, G. E.
(1969)
Biochim. Biophys. Acta
175,
1-9
[Medline]
[Medline]
[Order article via Infotrieve]
-
Harding, H. W. J., and Rogers, G. E.
(1971)
Biochemistry
10,
624-630
[CrossRef][Medline]
[Order article via Infotrieve]
-
Harding, H. W. J., and Rogers, G. E.
(1976)
Biochim. Biophys. Acta
427,
315-324
[Medline]
[Order article via Infotrieve]
-
Steinert, P. M.
(1978)
Biochemistry
17,
5045-5052
[Medline]
[CrossRef][Medline]
[Order article via Infotrieve]
-
Bradford, M. M.
(1976)
Anal. Biochem.
72,
248-254
[Medline]
[CrossRef][Medline]
[Order article via Infotrieve]
-
Laemmli, U. K.
(1970)
Nature
227,
680-685
[Medline]
[CrossRef][Medline]
[Order article via Infotrieve]
-
Kim, S.-Y., Kim, I.-G., Chung, S.-I., and Steinert, P. M.
(1994)
J. Biol. Chem.
269,
27979-27986
[Medline]
[Abstract/Free Full Text]
-
Sambrook, J., Fritsch, E. F., and Maniatis, T.
(1989)
Molecular Cloning:. A Laboratory Manual, 2nd Ed., pp. 17.36-17.44, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
-
Farnsworth, V., and Steinberg, K.
(1993)
Anal. Biochem.
215,
190-199
[Medline]
[CrossRef][Medline]
[Order article via Infotrieve]
-
Stark, G. R.
(1967)
Methods Enzymol.
11,
590-594
-
Rothnagel, J. A., and Steinert, P. M.
(1990)
J. Biol. Chem.
265,
1862-1865
[Medline]
[Abstract/Free Full Text]
-
Rickwood, D.
(1981)
Gel Electrophoresis of Proteins: A Practical Approach, IRL Press, Washington, D.C.
-
Marquesee, S., and Baldwin, R. L.
(1987)
Proc. Natl. Acad. Sci. U. S. A.
84,
8898-8902
[Abstract/Free Full Text]
-
Reynolds, J. A., and Tanford, C.
(1970)
J. Biol. Chem.
245,
5161-5165
[Medline]
[Abstract/Free Full Text]
-
Takagi, T., Tsujii, K., and Shirahama, K.
(1975)
J. Biochem. (Tokyo)
77,
939-947
[Medline]
[Abstract/Free Full Text]
-
Cohen, L. H., and Gotchel, B. V.
(1971)
J. Biol. Chem.
246,
1841-1848
[Medline]
[Abstract/Free Full Text]
-
Panyim, S., and Chalkley, R.
(1971)
J. Biol. Chem.
246,
7557-7560
[Medline]
[Abstract/Free Full Text]
-
Tung, J.-S., and Knight, C. A.
(1971)
Biochem. Biophys. Res. Commun.
42,
1117-1121
[Medline]
[CrossRef][Medline]
[Order article via Infotrieve]
-
Noel, D., Nikaidy, K., and Ames, G. F.-L.
(1979)
Biochemistry
18,
4159-4165
[Medline]
[CrossRef][Medline]
[Order article via Infotrieve]
-
Santucci, R., Brunori, M., and Ascoli, F.
(1987)
Biochim. Biophys. Acta
914,
185-189
[Medline]
[CrossRef][Medline]
[Order article via Infotrieve]
-
Goto, Y., Calciano, L. J., and Fink, A. L.
(1990)
Proc. Natl. Acad. Sci. U. S. A.
87,
573-577
[Medline]
[Abstract/Free Full Text]
-
Mei, G., Rosato, N., Silva, N., Rusch, R., Gratton, E., Savini, I., and Finazzi-Agrò, A.
(1992)
Biochemistry
31,
7224-7230
[Medline]
[CrossRef][Medline]
[Order article via Infotrieve]
-
Breslow, E., Beychok, D., Hardman, K. D., and Gurd, F. R. N.
(1965)
J. Biol. Chem.
240,
304-309
[Free Full Text]
-
Hughson, F. M., Wright, P. E., and Baldwin, R. L.
(1990)
Science
249,
1544-1548
[Medline]
[Abstract/Free Full Text]
-
Nomura, K.
(1992)
Arch. Biochem. Biophys.
293,
362-369
[Medline]
[CrossRef][Medline]
[Order article via Infotrieve]
-
Candi, E., Melino, G., Mei, G., Tarcsa, E., Chung, S.-I., Marekov, L. N., and Steinert, P. M.
(1995)
J. Biol Chem.
270,
26382-26390
[JBC][Medline]
[Abstract/Free Full Text]
-
Steinert, P. M., and Marekov, L. N.
(1995)
J. Biol. Chem.
270,
17702-17711
[JBC][Medline]
[Abstract/Free Full Text]
©1996 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
Y. Kamata, A. Taniguchi, M. Yamamoto, J. Nomura, K. Ishihara, H. Takahara, T. Hibino, and A. Takeda
Neutral Cysteine Protease Bleomycin Hydrolase Is Essential for the Breakdown of Deiminated Filaggrin into Amino Acids
J. Biol. Chem.,
May 8, 2009;
284(19):
12829 - 12836.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Sandilands, C. Sutherland, A. D. Irvine, and W. H. I. McLean
Filaggrin in the frontline: role in skin barrier function and disease
J. Cell Sci.,
May 1, 2009;
122(9):
1285 - 1294.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Uysal, R. Bockermann, K. S. Nandakumar, B. Sehnert, E. Bajtner, A. Engstrom, G. Serre, H. Burkhardt, M. M.G.M. Thunnissen, and R. Holmdahl
Structure and pathogenicity of antibodies specific for citrullinated collagen type II in experimental arthritis
J. Exp. Med.,
February 16, 2009;
206(2):
449 - 462.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Jang, E. Kim, J.-K. Choi, J.-K. Jin, J.-I. Kim, A. Ishigami, N. Maruyama, R. I. Carp, Y.-S. Kim, and E.-K. Choi
Accumulation of Citrullinated Proteins by Up-Regulated Peptidylarginine Deiminase 2 in Brains of Scrapie-Infected Mice: A Possible Role in Pathogenesis
Am. J. Pathol.,
October 1, 2008;
173(4):
1129 - 1142.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Nakayama-Hamada, A. Suzuki, H. Furukawa, R. Yamada, and K. Yamamoto
Citrullinated Fibrinogen Inhibits Thrombin-catalysed Fibrin Polymerization
J. Biochem.,
September 1, 2008;
144(3):
393 - 398.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Kizawa, H. Takahara, H. Troxler, P. Kleinert, U. Mochida, and C. W. Heizmann
Specific Citrullination Causes Assembly of a Globular S100A3 Homotetramer: A PUTATIVE Ca2+ MODULATOR MATURES HUMAN HAIR CUTICLE
J. Biol. Chem.,
February 22, 2008;
283(8):
5004 - 5013.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Arita, T. Shimizu, H. Hashimoto, Y. Hidaka, M. Yamada, and M. Sato
Structural basis for histone N-terminal recognition by human peptidylarginine deiminase 4
PNAS,
April 4, 2006;
103(14):
5291 - 5296.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. van Gaalen, A. Ioan-Facsinay, T. W. J. Huizinga, and R. E. M. Toes
The Devil in the Details: The Emerging Role of Anticitrulline Autoimmunity in Rheumatoid Arthritis
J. Immunol.,
November 1, 2005;
175(9):
5575 - 5580.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Chapuy-Regaud, M. Sebbag, D. Baeten, C. Clavel, C. Foulquier, F. De Keyser, and G. Serre
Fibrin Deimination in Synovial Tissue Is Not Specific for Rheumatoid Arthritis but Commonly Occurs during Synovitides
J. Immunol.,
April 15, 2005;
174(8):
5057 - 5064.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Chang, R. Yamada, A. Suzuki, T. Sawada, S. Yoshino, S. Tokuhiro, and K. Yamamoto
Localization of peptidylarginine deiminase 4 (PADI4) and citrullinated protein in synovial tissue of rheumatoid arthritis
Rheumatology,
January 1, 2005;
44(1):
40 - 50.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E R Vossenaar, T R D Radstake, A van der Heijden, M A M van Mansum, C Dieteren, D-J de Rooij, P Barrera, A J W Zendman, and W J van Venrooij
Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages
Ann Rheum Dis,
April 1, 2004;
63(4):
373 - 381.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. M. Steinert, D. A. D. Parry, and L. N. Marekov
Trichohyalin Mechanically Strengthens the Hair Follicle: MULTIPLE CROSS-BRIDGING ROLES IN THE INNER ROOT SHEATH
J. Biol. Chem.,
October 17, 2003;
278(42):
41409 - 41419.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Bas, T. V. Perneger, M. Seitz, J.-M. Tiercy, P. Roux-Lombard, and P. A. Guerne
Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors
Rheumatology,
July 1, 2002;
41(7):
809 - 814.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. B. Presland and B. A. Dale
Epithelial Structural Proteins of the Skin and Oral Cavity: Function in Health and Disease
Critical Reviews in Oral Biology & Medicine,
January 1, 2000;
11(4):
383 - 408.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Nakashima, T. Hagiwara, A. Ishigami, S. Nagata, H. Asaga, M. Kuramoto, T. Senshu, and M. Yamada
Molecular Characterization of Peptidylarginine Deiminase in HL-60 Cells Induced by Retinoic Acid and 1alpha ,25-Dihydroxyvitamin D3
J. Biol. Chem.,
September 24, 1999;
274(39):
27786 - 27792.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. M. Steinert, Y.-H. Chou, V. Prahlad, D. A. D. Parry, L. N. Marekov, K. C. Wu, S.-I. Jang, and R. D. Goldman
A High Molecular Weight Intermediate Filament-associated Protein in BHK-21 Cells Is Nestin, a Type VI Intermediate Filament Protein. LIMITED CO-ASSEMBLY IN VITRO TO FORM HETEROPOLYMERS WITH TYPE III VIMENTIN AND TYPE IV alpha -INTERNEXIN
J. Biol. Chem.,
April 2, 1999;
274(14):
9881 - 9890.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Candi, E. Tarcsa, W. W. Idler, T. Kartasova, L. N. Marekov, and P. M. Steinert
Transglutaminase Cross-linking Properties of the Small Proline-rich 1 Family of Cornified Cell Envelope Proteins. INTEGRATION WITH LORICRIN
J. Biol. Chem.,
March 12, 1999;
274(11):
7226 - 7237.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Girbal-Neuhauser, J.-J. Durieux, M. Arnaud, P. Dalbon, M. Sebbag, C. Vincent, M. Simon, T. Senshu, C. Masson-Bessiere, C. Jolivet-Reynaud, et al.
The Epitopes Targeted by the Rheumatoid Arthritis-Associated Antifilaggrin Autoantibodies are Posttranslationally Generated on Various Sites of (Pro)Filaggrin by Deimination of Arginine Residues
J. Immunol.,
January 1, 1999;
162(1):
585 - 594.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. M. Steinert, T. Kartasova, and L. N. Marekov
Biochemical Evidence That Small Proline-rich Proteins and Trichohyalin Function in Epithelia by Modulation of the Biomechanical Properties of Their Cornified Cell Envelopes
J. Biol. Chem.,
May 8, 1998;
273(19):
11758 - 11769.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Tarcsa, L. N. Marekov, J. Andreoli, W. W. Idler, E. Candi, S.-I. Chung, and P. M. Steinert
The Fate of Trichohyalin. SEQUENTIAL POST-TRANSLATIONAL MODIFICATIONS BY PEPTIDYL-ARGININE DEIMINASE AND TRANSGLUTAMINASES
J. Biol. Chem.,
October 31, 1997;
272(44):
27893 - 27901.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1996 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|